Abstract: Many probiotic formulations are available in the market and are advertised for several preventive or curative roles. The aim of this study was the identification of microorganisms composing different lactic acid bacteria based pharmaceutical formulations and the ascertainment of their ability to survive gastro-intestinal (GI) stresses, the main requisite to produce beneficial effects. For this purpose, viable bacteria were enumerated by plate counts in different media. Denaturing Gradient Gel Electrophoresis-Polymerase Chain Reaction (PCR-DGGE) analysis was applied on pure isolates and on crude formulations to confirm the composition in species. Also, crude formulations were subjected to stresses characteristic of the GI tract (GIT) to assess cell survival. Results highlighted concentrations lower than those reported in the labels in almost all the formulations. Moreover, some discrepancies were observed between reported species and those ascertained through the identification, and the use of an erroneous nomenclature was highlighted. The GI stress test revealed that bacteria are strongly injured, and this fact was evidenced by a marked reduction in viable counts after the stress. In conclusion, a widespread number of lactic acid bacteria based formulations are sold as probiotics, but their probiotic requisites are not adequately observed.
INTRODUCTION
Probiotic microorganisms are available in the market in different forms: probiotic foods, essentially milk-based fermented beverages [1] , and dried/lyophilized mono-or mixed cultures of probiotic microorganisms, in the form of powders, pills or tablets. If the former can be considered as "functional foods" (Regulation EC 178/2002) [2] , the latter represent a separate group, since tablets, pills or powders are not included in the technical definition of functional foods. As a consequence, the European market offers a widespread variety of probiotic formulations which can be considered as "border products", i.e. formulations that are neither food supplements, nor drugs, nor dietary supplements, because of the lack of an appropriate regulatory system [3] .
To be effective, probiotic strains must retain their functional health characteristics for which they were originally selected, including the ability to survive transit through the stomach and small intestine [4] . Also, the Joint FAO/WHO Expert Consultation [5] recommended that proper in vitro studies should be carried out to establish the potential health benefits of probiotics prior to undertaking in vivo trials. This matter was investigated with conflicting results; in fact, many Authors reported, on the one hand, the ability of some probiotic strains to survive stresses encountered during the passage through the GI tract (GIT), on the other hand, their low survival [6] [7] [8] [9] . Numerous techniques were assayed to evaluate the resistance to gastric juices and the ability to grow in the presence of bile under conditions in the intestine. In vitro protocols are commonly adopted [9] [10] [11] [12] , and tests are generally performed on rehydrated strains, sub-cultured in optimal conditions (appropriate medium, optimal temperature and O 2 concentration, etc.). In our opinion, the approach described above is not adequate for lyophilized formulations, since their ingestion, and subsequent passage from the mouth to the gut of the consumer, is not preceded by rehydration/activation steps. On these bases, in the present work pharmaceutical formulations, consisting of mono-or mixed cultures of lactic acid bacteria (LAB), were assayed to verify an important probiotic requisite, such as the resistance to those stresses which are typical of the GIT, without a preliminary rehydration step. The GI stress test was preceded by the enumeration of viable LAB in each pharmaceutical formulation and by the ascertainment of the identity in species, comparing results with those reported on the labels. These goals were reached through a multiple approach, based on the application of both culture-dependent and cultureindependent methods.
MATERIALS AND METHODS

Probiotic Formulations
Nine commercial formulations, consisting of monoor mixed cultures of Lactobacillus and Streptococcus species, were bought as probiotics in chemist's shops. Formulations were stored at 4°C and analysed before the "use by" date expiry. The main characteristics of the products are reported in Table 1 .
Presumptive Enumeration and Isolation of Viable Bacteria
The dried powder inside one sachet (dose) of each pharmaceutical formulation was aseptically weighed and 1:10 diluted in physiological sterile solution (9 g/L NaCl). Formulation J, in form of tablet (see Table 1 ), was roughly crumbled directly inside the blister to avoid contamination and then 1:10 diluted in physiological sterile solution. Samples were homogenized in a Stomacher 400 Lab Blender (PBI International, Milan, Italy) until their complete dissolution. Serial decimal dilutions were plated in appropriate culture media and optimal incubation conditions as follows:
Lactobacillus bulgaricus and Lb. casei (formulation A) were differently enumerated on MRS agar (Oxoid, Milan, Italy) at pH 5.2 (MRS pH 5.2) incubated at 43°C [13] and on MRS with 0.01% vancomycin (MRS-V) incubated at 37°C [14] , respectively. Those formulations containing Lb. rhamnosus (B and C), Lb. casei (E), Lb. paracasei (F), and Lb. reuteri (J) as single species were plated on MRS agar (Oxoid) incubated at 37°C (MRS 37°). Lb. paracasei and Lb. salivarius (formulation D) were differently enumerated on Homofermentative-Heterofermentative Differential (HHD) agar [14] incubated at 37°C. Tryptone Soy Agar plates incubated at 37°C (TSA 37°), specific for Bacillus coagulans, were used to enumerate Lb. sporogenes from formulation G [15] , since commercial products containing Bacillus coagulans use the invalid name "Lactobacillus sporogenes" on the label. Lb. acidophilus and Lb. bulgaricus from formulations G and H were differently counted on BA-maltose agar (BA-M) incubated at 37°C or in MRS pH 5.2 incubated at 43°C, respectively, both prepared as described by Tharmaraj and Shah [13] . Streptococcus thermophilus, also reported in G and H, was counted on M17 (M17 37°) agar (Oxoid) and in ST (ST 37°) agar, incubated at 37°C for 72h or for 24h, respectively, as described by Dave and Shah [16] . Incubation was performed in anaerobiosis (Anaerogen, Oxoid, Milan, Italy), except for B. coagulans (Lb. sporogenes) and S. thermophilus, Reference strain number reported on the label.
which required aerobic conditions. MRS agar (Oxoid) incubated at 37°C was regularly used to confirm lactobacilli counts and, if needed, to isolate colonies.
Counts were performed in duplicate on 2 different doses belonging to the same probiotic package.
Five to ten colonies of various forms and colour were randomly picked from agar plates containing between 30 and 300 colonies, purified by streaking in fresh media and maintained frozen at -80°C in microbanks (Pro-Lab Diagnostics, Richmond Hill, Canada) [17] .
Survival After Gastro-Intestinal Stresses
As before, the experiment was performed in duplicate on 2 different doses belonging to the same package, following the protocols described by de Palencia et al. [11] and by Ritter et al. [9] with some modifications. In detail, one dose (lyophilized powder or tablet) of each crude pharmaceutical formulation was transferred into a sterile 100 mL Drechsel bottle (Carlo Erba, Milan, Italy) coupled to a nitrogen cylinder. Fortyfive milliliters of sterile water was added in each bottle. To simulate the in vivo dilution of saliva, 10 mL of a sterile electrolyte solution (6.2 g/L NaCl, 2.2 g/L KCl, 0.22 g/L CaCl 2 and 1.2 g/L NaHCO 3 ) and then lysozyme (Sigma-Aldrich) to give a final concentration of 0.01% were added. To simulate the gastric environment, 10 mL of electrolyte solution containing 0.3% pepsin (final concentration, Sigma-Aldrich) was added and the pH was decreased to 2.0 by adding 1.0 mol/L HCl. Suspensions were incubated for 1 h in aerobic conditions. To simulate the intestinal stress, the oxygen was replaced by nitrogen to obtain an anaerobic atmosphere and pH was adjusted to 5.0 with a sodium bicarbonate saturated solution (8 g sodium bicarbonate in 100 mL distilled water, sterilized at 121°C for 15 min). Eight milliliters of a sterile electrolyte solution containing 0.45% bile salts and 0.1% pancreatin (final concentration, both from SigmaAldrich) were added. Then, pH was adjusted to 6.3 and slowly increased to 7.5 until the end of the assay (7 hours in all). The gastric and gastro-intestinal solutions were prepared fresh daily and the entire trial was performed at 37°C. Finally, formulations were analysed for cell survival by plate counts as follows:
MRS 37° in anaerobiosis for lactobacilli; b) M17 37° in aerobiosis for S. thermophilus; c) TSA 37°in aerobiosis for spore-forming bacteria.
DNA Extraction from Pure Cultures and PCR-DGGE Conditions
Pure frozen cultures isolated from each pharmaceutical formulation were revitalized in appropriate media. Two milliliters of each overnight culture was than centrifuged at 14 000 g for 10 min at 4°C (Centrifuge 5415 R; Eppendorf, Hamburg, Germany) to pellet the cells and the pellet was subjected to DNA extraction according to Querol et al. [18] , with the addition of lysozyme (25 mg/mL, Sigma) and mutanolysin (10 U/mL, Sigma) for bacterial cellwall digestion. The DNA from each strain was than prepared for DGGE by amplifying the V1 region of 16S rRNA using the following primers: P1V1 (5'-GCG GCG TGC CTA ATA CAT GC-3') and P2V1 (5'-TTC CCC ACG CGT TAC TCA CC-3') [19] . A GC clamp (5'-CGC CCG CCG CGC CCC GCG CCC GTC CCG CCG CCC CCG CCC G-3') [20] was attached to the 5' end of the P1V1 primer. Negative controls without DNA template were included in parallel. PCR and gel processing were performed as described by Reale et al. [21] .
Sequence Analysis
One representative strain from each cluster obtained by DGGE analysis was amplified with primers P1 and P4, as described by Klijn et al. [19] , targeting 700 bp of the V1-V3 region of the 16S rRNA gene. After purification (QIAquick PCR purification kit, QIAGEN GmbH, Hilden, Germany), products were sent to a commercial facility for sequencing (Eurofins MWG Biotech Company, Ebersberg, Germany). Sequences were aligned with those in GenBank with the Blast program to determine the closest known relatives, based on the partial 16S rRNA gene homology.
Direct DNA Extraction from Crude Formulations and PCR-DGGE Conditions
The direct extraction of nucleic acids from pharmaceutical formulations was performed according to Iacumin et al. [22] . The DNA from each formulation was then prepared for PCR-DGGE as described above. The DNA of 12 strains, previously isolated from pharmaceutical formulations and identified by sequencing, was re-subjected to DGGE analysis for comparative purposes. Gels were then normalized with the pattern analysis software package, Gel Compare II Version 2.0 (Applied Maths).
RESULTS
Viable Counts Before and After GI Stresses
Microbial concentrations reported on the label of the pharmaceutical formulations were compared with In the multiple-strain formulation H, MRS 37° was the sole medium that allowed the growth of lactobacilli, which resulted present with counts of about 7 logs, in accordance with data reported in the label. No colony was evidenced in BA-M or in MRS pH 5.2. Once again, M17 37° showed the best ability to detect S. thermophilus, whose amount confirmed the reported load (about 9 logs), whereas no colony was evidenced in ST 37° after 24 h incubation.
As for single-strain formulations, the microbial load resulted about 1 log lower than that declared in B and C, and about 2 logs lower in E and F. The sole formulation J showed viable counts about 1 log higher than that reported.
Overall, counts registered in appropriate media highlighted the presence of high numbers of viable bacteria for all assayed formulations. The situation after GI stresses indicated a very high injury for almost all bacteria ( Table 2 ). The highest damage was highlighted for lactobacilli of formulation A and S. thermophilus of H, which evidenced a reduction in counts of 7.1 and 6.7 logs, respectively, after GI stresses. Also in formulations B and C a drastic reduction of viable lactobacilli was highlighted, as evidenced by counts of 5.9 and 6 logs lower after GI stresses. On the other hand, microorganisms contained in G showed a good ability to survive harsh conditions, as demonstrated by counts after GI stresses of about 1.4-2.5 logs lower than those registered prior the assay. All the other pharmaceutical formulations (D, E, F, H and J) showed counts of lactobacilli from 4.5 to 5.5 logs lower after GI stresses.
DGGE Analysis
Migration profiles obtained by DGGE analysis of pure cultures allowed the individuation of 18 clusters with 80% similarity level, arbitrarily chosen for defining species (Figure 1) . One strain belonging to each cluster was than subjected to sequencing for identification purposes. On the basis of the results of sequencing ( Table 3 ) and cluster analysis (Figure 1) it was possible to correctly identify 10 strains as S. thermophilus (clusters 1 and 3), 9 strains as Bacillus coagulans (clusters 2, 6 and 7), 5 strains as Lb. delbrueckii ssp. bulgaricus (clusters 4 and 5), 5 strains as Lb. reuteri (cluster 8), 9 strains as Lb. paracasei (clusters 9 and 12), 10 strains as Lb. rhamnosus (clusters 10, 11 and 13), 6 strains as Lb. salivarius (cluster 14), 6 strains as Lb. acidophilus (cluster 15), and 15 strains as Lb. casei (clusters 16, 17 and 18) . Comparing these results with the species reported on the labels of formulations (Table 1) , we found a full correspondence for 6 products (B, C, D, E, F and J) and a partial one for the remaining 3 (A, G and H). In detail, in preparation A, 5 isolates were obtained from plates of MRS-V and 5 from MRS 37°, since MRS pH 5.2 did not allow the isolation of colonies (see Table 2 ). All the isolates were identified as Lb. casei (clusters 16 and 17, Figure 1) , whereas Lb. bulgaricus, also reported in the label, was not found out. This datum confirmed results obtained by plate counts, i.e. the absence of colonies in MRS pH 5.2 incubated at 43°C.
Ten colonies were isolated from MRS 37° plates used for microbial counts of formulations B and C and were grouped into clusters 10, 11 and 13 (Figure 1) , confirming the sole presence of Lb. rhamnosus in those formulations. Six out of 10 isolates from D were identified as Lb. salivarius (Figure 1, cluster 14) , while the remaining 4 isolates were identified as Lb. paracasei (cluster 12), confirming the microbial composition reported on the label.
All the colonies isolated from the single-strain formulation E were grouped into the cluster 18 and identified as Lb. casei. Analogously, all the strains of Lb. paracasei or Lb. reuteri from single-strain formulations F or J, respectively, were grouped into clusters 9 or 8 (Figure 1) , confirming data reported on labels.
As for formulations G and H, some discrepancies were underlined between data obtained in our work
and what reported in the labels. In fact, Lb. bulgaricus was not found in formulation G; moreover, in the same formulation the species reported as Lb. sporogenes was correctly identified as B. coagulans by sequence analysis (Table 3 and Figure 1 , clusters 2, 6 and 7). As previously reported for A, also in G the absence of Lb. bulgaricus seemed to be confirmed by the absence of colonies in MRS pH 5.2 incubated at 43°C. To confirm results obtained in the media used for lactobacilli counts, MRS agar was used to isolate 5 additional colonies, but all the isolates resulted ascribable to Lb. acidophilus or B. coagulans.
With regard to formulation H, no growth was detected in MRS pH 5.2 nor in BA-M; once again, MRS agar was used to isolate colonies of presumptive lactobacilli. All of them were identified as Lb. bulgaricus (Figure 1 , clusters 4 and 5) whereas Lb. acidophilus, also reported in the label, was not found. S. thermophilus was isolated from M17 plates, in confirmation of the presence of this species in formulation H. DGGE analysis performed on the DNA directly extracted from crude formulations partially confirmed the results reported earlier. In particular, the profile A Accession number of the sequence of the closest relative found by BLAST search.
( Figure 2 ) showed 3 bands (A1, A2 and A3) corresponding to those of Lb. casei A, the sole species isolated from this formulation. The lane A also showed the presence of one other band, marked as A4, which was absent in the lane of Lb. casei A and which could be imputable to Lb. delbrueckii ssp. bulgaricus, the second species indicated in the label of formulation A, and whose presence was not confirmed by the culturedependent method used in this study.
Profiles of both formulations B and C (Figure 2 ) evidenced the presence of only one band, indicated as B-C1, corresponding to that of Lb. rhamnosus B and C, isolated from both formulations B and C and grouped in the same cluster, as reported earlier (Figure 1) . Band B1, characterizing the profile of 2 Lb. rhamnosus strains also isolated from formulation B (Figure 1,   cluster 13 ), was not detectable in the profile B. Lane D evidenced the presence of one band marked as D1, which corresponded to that of Lb. salivarius D, whereas the band D2 did not correspond to the band D3 of Lb. paracasei D, the second species isolated from this formulation, whose presence was also reported in the label.
The profile of the single-strain formulation E was characterized by the presence of band E1, which corresponded to that of Lb. casei E. Four bands (F1-F4) were present in the profile F and all resulted attributable to Lb. paracasei ssp. paracasei F, isolated from this single-strain formulation.
Lane G showed the presence of one band, marked as G1, which corresponded to that of Lb. acidophilus G. The profile of G did not show any other bands, neither those distinctive of B. coagulans G, erroneously labelled as Lb. sporogenes (bands G2 and G3), or S. thermophilus G (band G-H1), both isolated from this formulation, nor those of Lb. delbrueckii ssp. bulgaricus, the other species reported in the label, whose presence was not confirmed by culturedependent methods. The multiple-strain formulation H showed 2 bands, marked as G-H1 and H2. If the former was attributable to S. thermophilus H (band G-H1), the latter did not correspond to any bands of Lb. delbrueckii ssp. bulgaricus H (bands H3-H5), the second species detected through the use of culturedependent techniques. Interestingly, the band H2 was in the same migration position of band G1 (lane G), referring to Lb. acidophilus G, even if this species was not detectable in formulation H by culture-dependent methods. Finally, the profile of formulation J showed at least two bands (J1 and J2) referring to Lb. reuteri J, the sole species reported in the label of this pharmaceutical product.
DISCUSSION
It is well known that the ability of probiotic microorganisms to provide health benefits is strictly related to the amount of viable bacteria able to reach the large intestine. With regard to commercial probiotic formulations, this information should be deductible by the label of each product, since it is not possible to provide one minimum dose for all products, because different probiotics are effective at different levels [23] . In our study, this information was reported for all the products under analysis, but in the case of multi-strain formulations the concentration of each microorganism was reported in two cases (A and H), in some others (D and G), only the total number was indicated in the label. Moreover, the reported number of live microorganisms delivered in each serving dose was about 8-9 logs, but we found in almost all the commercial formulations a number of viable bacteria lower than that indicated. In this connection, it is just the case to remember that some Authors supposed a positive role attributable to the administration of dead cells of probiotics or of their DNA [24] [25] [26] . Nevertheless, data recorded in our work can be considered reassuring, taking into account that counts were always included in the generally accepted range for probiotic efficacy (between 7 and 9 logs live microorganisms daily/dose).
With regard to the effective presence of species reported on the labels, the concurrent application of both culture-dependent and independent methods gave different results. In detail, it is generally accepted that DGGE analysis can be considered an appropriate method for directly analysing microbial communities when abundance is greater than 5 logs. So, it seemed to be a suitable approach for probiotic preparations, where concentrations reported were about 8-9 logs. However, results obtained in this study showed that the best approach consists in the concurrent application of both culture-dependent methods, based on the isolation and identification of cultivable bacteria, and independent PCR-DGGE, directly applied on crude preparations. In fact, the first method allowed the identification of viable bacteria whereas the latter revealed the presence of the DNA of some species, such as Lb. bulgaricus in A and Lb. acidophilus in G, which were not detected through the isolation technique. This fact could be imputable to the culture media used in this study. For instance, in our work we ascertained the unsuitability of MRS pH 5.2 to isolate Lb. delbrueckii ssp. bulgaricus, probably due to the use of an incubation temperature (43°C) too high for lactobacilli selected for probiotic purposes. As for HHD, this medium seems more suitable for the selective enumeration of obligately homo-and heterofermentative lactobacilli species than homo-and facultative hetero-fermentative ones [27] , since it did not allow the expected discrimination between Lb. salivarius and Lb. paracasei based on defined colony colours. However, it should be reminded that MRS agar was used to count and isolate lactobacilli when other specific media did not allow the growth of colonies and, in our opinion, MRS represents an excellent medium for the cultivation of lactobacilli, even if it does not allow the discrimination between different species. Also, ST agar, proposed to selectively enumerate S. thermophilus at 37°C after 24 h incubation, did not allow the growth of this species nor of other ones.
Apart from this interpretation, we can also assume that several factors influenced the stability and viability of searched LAB, and for these reasons some species were not detectable by culture-dependent methods because damages suffered during the industrial phases of production compromised their viability. This fact is probably imputable to the severity of processing conditions adopted to produce dried cultures, as already reported by Aureli et al. [14] . Furthermore, the decay of viable cell count is considered a typical phenomenon of every probiotic formulation [28] .
In our work, we also highlighted the use of an inappropriate nomenclature in one product, i.e. Lb. sporogenes instead of B. coagulans. In our opinion, the facts reported above have to be taken into serious account, since the consumer has the right to receive a correct information regarding the composition of microbial cultures used for probiotic purposes. Moreover, the inappropriateness of microbial species reported on the labels represents a problem for the researchers. In fact, we did not find the reference strain number for all bacteria composing pharmaceutical preparations under analysis, while the Food and Agriculture Organization, as well as the World Health Organization [5] , strongly recommend the deposit of probiotic bacteria in international culture collections in order to facilitate their identification.
Data regarding the resistance of bacterial formulations to GI stresses evidenced a drastic reduction in viable counts. In detail, the approach used in this study was scheduled in order to mime the ingestion of formulations, and the subsequent passage of microorganisms from the mouth to the gut of the consumer, without preparatory rehydration/activation steps, generally used to test the survival of probiotic strains during the passage through the GIT [9, 29, 30] . We observed a high rate of injured/dead cells, with counts up to 7.4 logs lower after GI stresses in several probiotic formulations. In vivo food intake probably protects bacteria during gastric passage, and the use of simulated human juices and bile salt formulations could drastically influence the survival of probiotic bacteria. However, it is also well known the fact that these microorganisms are often poorly adapted to conditions encountered in the GIT and their delivery from the mouth to the large intestine remains the major problem for their use in human therapies [31] .
In conclusion, this work documented the need to regulate the marketing of probiotic products and to establish routinely and well-defined checks able to assess their real composition and efficacy. Further studies will be carried out in order to verify the viability and resistance to GI stresses of probiotic lactic acid bacteria in probiotic foods.
